Alan W. Harris
#166,931
Most Influential Person Now
Alan W. Harris's AcademicInfluence.com Rankings
Alan W. Harrisbiology Degrees
Biology
#13562
World Rank
#17114
Historical Rank
Genetics
#1520
World Rank
#1623
Historical Rank
Molecular Biology
#2308
World Rank
#2343
Historical Rank
Neuroscience
#2365
World Rank
#2429
Historical Rank
Download Badge
Biology
Alan W. Harris's Degrees
- PhD Molecular Biology University of California, Berkeley
- Bachelors Biochemistry Stanford University
Why Is Alan W. Harris Influential?
(Suggest an Edit or Addition)Alan W. Harris's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice (1985) (1744)
- bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship (1991) (1132)
- Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 (1990) (939)
- Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. (1991) (852)
- Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis. (1995) (774)
- DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 (1994) (707)
- Elimination of self-reactive B lymphocytes proceeds in two stages: Arrested development and cell death (1993) (561)
- Bim is a suppressor of Myc-induced mouse B cell leukemia. (2004) (510)
- A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes (1998) (480)
- Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. (1994) (473)
- Mouse myelomas and lymphomas in culture. (1970) (462)
- Lymphomas in E mu-Pim1 transgenic mice exposed to pulsed 900 MHZ electromagnetic fields. (1997) (450)
- The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice (1986) (449)
- Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. (2002) (436)
- The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells (1988) (422)
- Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. (1999) (376)
- Bethesda proposals for classification of lymphoid neoplasms in mice. (2002) (344)
- Glucocorticoid Receptors in Lymphoma Cells in Culture: Relationship to Glucocorticoid Killing Activity (1971) (228)
- Interferon-gamma induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines. (1983) (221)
- bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. (1993) (200)
- VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. (2004) (197)
- Effect of cloned interferon‐γ on expression of H‐2 and Ia antigens on cell lines of hemopoietic, lymphoid, epithelial, fibroblastic and neuronal origin (1984) (190)
- Mutations in the p53 and SCID genes cooperate in tumorigenesis. (1996) (186)
- Differentiated functions expressed by cultured mouse lymphoma cells. II. Theta antigen, surface immunoglobulin and a receptor for antibody on cells of a thymoma cell line. (1973) (170)
- Bcl-2 expression promotes B- but not T-lymphoid development in scid mice (1994) (169)
- E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. (1993) (168)
- Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. (1999) (165)
- Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. (1999) (162)
- Positive and negative selection of T cells in T-cell receptor transgenic mice expressing a bcl-2 transgene. (1994) (152)
- Enforced Bcl-2 Expression Inhibits Antigen-mediated Clonal Elimination of Peripheral B Cells in an Antigen Dose–dependent Manner and Promotes Receptor Editing in Autoreactive, Immature B Cells (1997) (149)
- FADD/MORT1 regulates the pre‐TCR checkpoint and can function as a tumour suppressor (2000) (145)
- Expression of the immunoglobulin C mu gene in mouse T and B lymphoid and myeloid cell lines. (1980) (137)
- Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. (1990) (135)
- Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes (1995) (132)
- A bcr-v-abl oncogene induces lymphomas in transgenic mice (1989) (124)
- N‐myc transgene promotes B lymphoid proliferation, elicits lymphomas and reveals cross‐regulation with c‐myc. (1989) (113)
- Mechanism of glucocorticoid action: general features, with reference to steroid-mediated immunosuppression. (1975) (109)
- Cell-mediated immune response in vitro. II. The role of thymus and thymus-derived lymphocytes. (1972) (106)
- Differentiated functions expressed by cultured mouse lymphoma cells. I. Specificity and kinetics of cell responses to corticosteroids. (1970) (97)
- Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. (1998) (96)
- Immunoglobulin of T lymphoma cells. Biosynthesis, surface representation, and partial characterization. (1975) (94)
- Transferrin promotion of 67Ga and 59Fe uptake by cultured mouse myeloma cells. (1977) (91)
- Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. (1997) (86)
- Effects of a dominant interfering mutant of FADD on signal transduction in activated T cells (2001) (83)
- An E mu‐v‐abl transgene elicits plasmacytomas in concert with an activated myc gene. (1990) (80)
- Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector (1999) (78)
- Transcripts of the immunoglobulin C mu gene vary in structure and splicing during lymphoid development. (1980) (78)
- Progenitor tumours from Emu‐bcl‐2‐myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. (1996) (72)
- FADD and caspase-8 are required for cytokine-induced proliferation of hemopoietic progenitor cells. (2005) (69)
- CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types. (2000) (68)
- Effect of thymidine on the sensitivity of cultured mouse tumor cells to 1-beta-D-arabinofuranosylcytosine. (1979) (65)
- MYC levels govern hematopoietic tumor type and latency in transgenic mice. (2006) (63)
- Subunit structure of cell surface proteins: disulfide bonding in antigen receptors, Ly-2/3 antigens, and transferrin receptors of murine T and B lymphocytes. (1981) (63)
- Activation of mouse lymphocytes inhibits induction of rapid cell death by x-irradiation. (1985) (61)
- Differential expression of the invariant chain in mouse tumor cells: relationship to B lymphoid development. (1984) (58)
- Intermediate steps in thymic positive selection. Generation of CD4-8+ T cells in culture from CD4+8+, CD4int8+, and CD4+8int thymocytes with up-regulated levels of TCR-CD3. (1995) (56)
- The immunoglobulin μ constant region gene is expressed in mouse thymocytes (1980) (55)
- Atlas Of Mouse Hematopathology (2000) (54)
- Gallium-67 citrate uptake by cultured tumor cells, stimulated by serum transferrin. (1975) (54)
- bcl-2 transgene expression promotes survival and reduces proliferation of CD3-CD4-CD8- T cell progenitors. (1997) (53)
- Deoxyribonucleoside triphosphate pools and differential thymidine sensitivities of cultured mouse lymphoma and myeloma cells. (1979) (50)
- Alkaline phosphatase in hematopoietic tumor cell lines of the mouse: high activity in cells of the B lymphoid lineage. (1981) (49)
- Enforced BCL 2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease ( oncogene / transgenic mice / lymphocyte lifespan / lupus mkce / glomerulonephritis ) (47)
- A test of lymphoma induction by long-term exposure of E mu-Pim1 transgenic mice to 50 Hz magnetic fields. (1998) (47)
- Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. (1992) (47)
- Receptors for immunoglobulin on B lymphocytes and cells of a cultured plasma cell tumor. (1972) (44)
- CD4+8- and CD4-8+ mature thymocytes require different post-selection processing for final development. (1993) (43)
- T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC (2005) (42)
- Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice. (1995) (42)
- Control of apoptosis in hematopoietic cells by the Bcl-2 family of proteins. (1999) (41)
- Ga-67 and Fe-59 distributions in mice. (1978) (41)
- Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl. (1989) (37)
- Insights from transgenic mice regarding the role of bcl-2 in normal and neoplastic lymphoid cells. (1994) (37)
- Transgenic mouse models for hematopoietic tumorigenesis. (1988) (35)
- Subversion of the Bcl-2 life/death switch in cancer development and therapy. (2005) (35)
- Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy. (1988) (34)
- Multiple genetic loci modify susceptibility to plasmacytoma-related morbidity in Eμ-v-abl transgenic mice (2002) (33)
- Immunoglobulin production by murine B-lymphoma cells. (1981) (33)
- B-lymphoid to granulocytic switch during hematopoiesis in a transgenic mouse strain. (1994) (32)
- Enhanced cell survival and tumorigenesis. (1994) (32)
- Perturbed development of T and B cells in mice expressing an Hlx homeobox transgene. (1995) (32)
- In vivo activity of in vitro immunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes. (1972) (29)
- MOLECULAR PROPERTIES OF T LYMPHOMA IMMUNOGLOBULIN (1977) (28)
- Production of RNA for secreted immunoglobulin μ chains does not require transcriptional termination 5′ to the μM exons (1983) (26)
- Lessons from bcl-2 transgenic mice for immunology, cancer biology and cell death research. (1996) (24)
- INHIBITION OF A T-CELL-DEPENDENT IMMUNE RESPONSE IN VITRO BY THYMOMA CELL IMMUNOGLOBULIN (1974) (24)
- SPECULATIONS ON THE FUNCTION OF IMMUNE RESPONSE GENES (1974) (24)
- Generation of long mRNA for membrane immunoglobulin γ2a chains by differential splicing (1981) (22)
- Cells of some cultured lymphoma lines are killed rapidly by x-rays and by bleomycin. (1982) (19)
- Immunoglobulin Cμ RNA in T lymphoma cells is not translated (1980) (17)
- Studies on the uptake of 67 Ga and 59 Fe and the binding of transferrin by cultured mouse tumour cells. (1981) (16)
- Use of [75Se]selenomethionine in immunoglobulin biosynthetic studies. (1978) (15)
- Effect of a bcl-2 transgene on production and localization of precursor B cells in mouse bone marrow. (1998) (14)
- The role of bcl-2 in lymphoid differentiation and neoplastic transformation. (1992) (14)
- c-myc-induced lymphomagenesis in transgenic mice and the role of the Pvt-1 locus in lymphoid neoplasia. (1986) (14)
- Moloney virus induction of T‐cell lymphomas in a plasmacytomagenic strain of Eμ‐V‐ABL transgenic mice (1993) (13)
- Genetic studies on Emu-myc transgenic mice. (1988) (13)
- Detection of a possible precursor of immunoglobulin light chain in MOPC 41 a plasmacytoma cells (1975) (12)
- Lymphomas and plasmacytomas in transgenic mice involving bcl2, myc and v-abl. (1997) (12)
- Plasma membrane of a murine T cell lymphoma: surface labelling, membrane isolation, separation of membrane proteins and distribution of surface label amongst these proteins. (1976) (12)
- beta-Adrenergic receptors and adenylate cyclase activity in murine lymphoid cell lines. (1985) (12)
- A B lymphoma cell line produces growth factors for hemopoietic, lymphoid, and mast cells. (1982) (11)
- Lymphoid tumorigenesis by v-abl and BCR-v-abl in transgenic mice. (1990) (11)
- Transferrin Promotion of 67 Gaand 59 FeUptake by Cultured MouseMyelomaCells 1 (10)
- mu Polypeptide phenotypes of lymphoid and myeloid cell lines containing RNA transcripts of the immunoglobulin C mu gene. (1981) (10)
- The myc oncogene and lymphoid neoplasia: from translocations to transgenic mice. (1987) (9)
- Cyclin D1 as the putative bcl-1 oncogene. (1995) (6)
- Variations in cellular sensitivity to glucocorticoids: observations and mechanisms. (1979) (5)
- Lessons from Translocations and Transgenic Mice: Constitutive c-myc Expression Predisposes to Neoplasia (1986) (5)
- Deregulation of cell survival in lymphomagenesis. (1997) (4)
- CELL SURFACE IMMUNOGLOBULIN OF MOUSE T LYMPHOMA CELLS AND CULTURED FETAL THYMOCYTES (1976) (4)
- A phase 1 dose escalation study of RAD1901, an oral selective estrogen receptor degrader, in healthy postmenopausal women (2016) (4)
- The transgenic window on lymphoid malignancy. (1989) (4)
- RAD1901, a novel tissue-selective estrogen receptor degrader (SERD) demonstrates estrogen receptor engagement in a phase 1 clinical study (2015) (4)
- Expression of the immunoglobulin C , gene in mouse T and B lymphoid and myeloid cell lines ( p and K mRNA species / hibridization / recombinant DNA / rearranged genes ) (4)
- Lymphocyte differentiation as analyzed by the expression of defined cell surface markers. (1978) (4)
- Growth Control of Hemopoietic Colony-Forming Cells by Thymidine and Deoxycytidine (1979) (3)
- Transferrin promotion of /sup 67/Ga and /sup 59/Fe uptake by cultured mouse myeloma cells (1977) (2)
- Oncogene cooperation and B-lymphoid tumorigenesis in Emu-myc transgenic mice. (1989) (2)
- Receptors for immunoglobulin on b lymphocytes and cells of a plasma cell tumor. Abstr. (1971) (1)
- Decreased cell death and increased self‐renewal: two facets of hematopoietic cell transformation (1992) (1)
- Immunoglobulin Gene Expression in Murine Lymphoid Cells (1973) (1)
- Contribution of the Cyclin D1 Gene to Lymphomagenesis (1995) (0)
- Table of Contents (1995) (0)
- Lymphoid neoplasia and the control of haemopoietic differentiation. (1989) (0)
- The Role of bcl — 2 in Lymphoid Differentation and Transformation (1993) (0)
- Transgenic Window on Haematopoietic Neoplasia (1990) (0)
- Positive and negative selection of T cells in T-cell receptor transgenic mice expressing a bc1-2 transgene (0)
- Transgenic Mice as Models for the Development of Haemopoietic Neoplasia (1989) (0)
- Constitutive c myc expression and lymphoid neoplasia (1987) (0)
- INHIBITION O F A T-CELL-DEPENDENT I MMUNE R ESPONSE I N VITRO B Y T HYMOMA C ELL I MMUNOGLOBULIN* (1974) (0)
- the Hematopoietic Compartment Drive Transgene Expression In Vivo Throughout vav Promoter Elements of (2010) (0)
- Mouse Myeloma Cells1 (1977) (0)
- Production of RNA for secreted immunoglobulin mu chains does not require transcriptional termination 5' to the microM exons. (1983) (0)
- Homeobox Genes in Hematopoiesis (1992) (0)
- The Bcl-2 Family: Arbiters of Life and Death (2000) (0)
- Oncogene impact on haemopoietic cells (1989) (0)
- hemopoietic progenitor cells FADD and caspase-8 are required for cytokine-induced proliferation of (2013) (0)
- How, when, and why do lymphocytes die? (2000) (0)
- Generation of long mRNA for membrane immunoglobulin gamma 2a chains by differential splicing. (1981) (0)
- An immunocompetent E mu-myc mouse B leukemia/lymphoma model for studying Bcl-2 related chemoresistance in vivo. (2003) (0)
This paper list is powered by the following services:
